Tectonic Therapeutic, Inc. quarterly report, Q3 FY2020

Business context and reporting period

Entity discrepancy: The supplied filing is AVROBIO, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2020, filed November 5, 2020. It does not appear to be a filing by Tectonic Therapeutic, Inc.; verify the issuer before relying on this summary.

AVROBIO is a clinical-stage gene therapy company developing ex vivo lentiviral treatments for rare diseases. It reported no product revenue and had five programs: Fabry, cystinosis, Gaucher, Hunter and Pompe disease.

Financial results and position

Amounts below are in U.S. dollars, millions, except per-share data. The filing presents no gross profit or operating margins; with no product sales, these are not meaningful.

At September 30, cash and cash equivalents were $219.5 million, versus $187.0 million at December 31, 2019. Current assets were $229.0 million and current liabilities $25.1 million. Total liabilities were $25.4 million; the filing reports no debt balance. Nine-month investing cash use was $1.1 million, while financing provided $101.9 million, primarily from the February 2020 offering ($93.6 million net) and ATM sales ($8.1 million net). Cash, cash equivalents and restricted cash increased $32.5 million to $220.0 million.

Material changes versus prior comparable periods

• Q3 net loss more than doubled year over year, rising $19.6 million; nine-month net loss increased $41.3 million.
• R&D expense increased $15.5 million in Q3 and $29.9 million for the nine-month period. Drivers included higher personnel and other unallocated costs, increased program activity, and an $8.0 million Hunter-program license fee.
• G&A expense rose $3.2 million in Q3 and $9.9 million year to date, primarily from personnel, facilities and professional costs.
• Interest income declined to $12,000 in Q3 and $0.7 million year to date, compared with $0.9 million and $2.1 million, respectively, in 2019, reflecting lower money-market yields.
• Share count increased: 36.449 million shares were outstanding at September 30, compared with 31.643 million at year-end 2019, following equity offerings and ATM issuance.

Outlook, commentary, risks and unusual items

• Management estimated existing cash would fund planned operating expenses and capital expenditures into the second half of 2022; the notes also state cash should cover at least the next 12 months from the filing date. These are estimates based on assumptions, and further financing will be needed thereafter if operations continue as planned.
• Management expects losses and expenses to increase as programs advance. The company has never generated product revenue and may never achieve profitability.
• COVID-19 had temporarily paused some new-patient dosing and delayed some data collection. Activities had begun resuming, but further disruption to enrollment, trials, suppliers or operations remained possible.
• On September 30, AVROBIO entered an exclusive worldwide Hunter syndrome license with the University of Manchester and expensed an $8.0 million upfront fee. The agreement also provides for up to $80 million in development and regulatory milestones, royalties, and funding of a university-sponsored Phase 1/2 trial estimated at approximately £9.1 million. No CRFA costs had been recognized at September 30.
• Clinical updates included four patients dosed in the company-sponsored Fabry Phase 2 trial, two in the cystinosis investigator-sponsored trial and one in the Gaucher Phase 1/2 trial. A Hunter Phase 1/2 investigator-sponsored trial was expected to begin in the second half of 2021; Pompe remained preclinical.
• Management said the disclosure controls and procedures were ineffective at September 30 because previously identified material weaknesses in financial reporting controls had not been fully remediated. Management nevertheless stated that the interim financial statements fairly presented the company’s financial position and results in accordance with U.S. GAAP.
• Other risks include clinical and regulatory uncertainty, gene-therapy safety and manufacturing challenges, reliance on third parties and limited suppliers, and intellectual-property and licensing risks. The company reported no material legal proceedings and no significant off-balance-sheet arrangements.

Important facts for investors to verify

• Confirm the issuer: the supplied document identifies AVROBIO, Inc., not Tectonic Therapeutic, Inc.
• Review the assumptions behind the stated cash runway and expected timing and amount of future financing.
• Assess trial enrollment, COVID-related delays, emerging efficacy and safety data, and comparability requirements for AVROBIO’s commercial-scale manufacturing platform.
• Track the Hunter license’s trial-funding obligations and potential milestone, royalty and sublicense payments.
• Monitor remediation of the material weaknesses and the effectiveness of financial reporting controls.
• Evaluate continuing operating cash burn, expense growth and dilution from equity financing and outstanding equity awards.